Literature DB >> 17473302

FDA responds to institute of medicine drug safety recommendations--in part.

Bruce M Psaty1, R Alta Charo.   

Abstract

Mesh：

Year:  2007        PMID： 17473302     DOI： 10.1001/jama.297.17.1917

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  4 in total

1.  Preemption, tort reform, and pharmaceutical claims: Part two: Has the Food and Drug Administration shown it is solely responsible for the protection of patients? Can it do so? Will it do so?

Authors:  Russell G Thornton
Journal:  Proc (Bayl Univ Med Cent)       Date:  2008-01

2.  Safety monitoring of drugs receiving pediatric marketing exclusivity.

Authors:  P Brian Smith; Daniel K Benjamin; M Dianne Murphy; Rosemary Johann-Liang; Solomon Iyasu; Barbara Gould; Robert M Califf; Jennifer S Li; William Rodriguez
Journal:  Pediatrics       Date:  2008-09       Impact factor: 7.124

Review 3.  Pharmacovigilance: methods, recent developments and future perspectives.

Authors:  L Härmark; A C van Grootheest
Journal:  Eur J Clin Pharmacol       Date:  2008-06-04       Impact factor: 2.953

4.  Using clinical trial data and linked administrative health data to reduce the risk of adverse events associated with the uptake of newly released drugs by older Australians: a model process.

Authors:  Margaret T Whitstock; Christopher M Pearce; Stephen C Ridout; Elizabeth J Eckermann
Journal:  BMC Public Health       Date:  2011-05-21       Impact factor: 3.295
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.